GlobeNewsWire
01 Jul 2026, 12:42 UTC · 12w ago
Verdict
Headline takes no side. We score ARTL +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Artelo Biosciences announced positive preclinical data showing that ART26.12 alleviates neuropathic pain associated with spinal cord injury in animal models.
More positive than 77% of claims this week
The results expand the potential clinical utility of ART26.12 beyond its previously reported target indications in painful neuropathies.
So whatExpanding the Total Addressable Market (TAM) for a lead candidate increases the potential long-term valuation of the company.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
ART26.12 is currently progressing through Phase 1 human development and has previously demonstrated a favorable safety profile with no serious adverse events.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company announced positive preclinical data supporting the potential of its lead candidate, ART26.12, for treating chronic pain associated with spinal cord injury.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
20h ago
+12.7%
Price agrees with the score
$11.36 vs $10.08 close before publication (Jun 30) · not market-adjusted
ARTL chart →
